Arthritis Research
Arthritis is an inflammatory disease of the joints, including the synovium, cartilage, bone, and supporting tissues. It is the leading cause of disability in the US and there are over 100 different types of the disease. The most common types of arthritis are osteoarthritis, rheumatoid arthritis and gout.
Arthritis Research Products Targets
- Matrix Metalloprotease (16)
- Cell Adhesion Molecule (21)
- Leukotriene and Related Receptor (13)
- Others (7)
- Glucocorticoid Receptor (9)
- Cyclooxygenase (24)
- Complement (2)
- Focal Adhesion Kinase (4)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- p38 MAPK (16)
- Janus N-terminal Kinase (12)
- Calcium-Sensitive Protease Modulator (12)
- Rho-Kinases (9)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Cytokine (15)
Products for Arthritis Research - Page 14
- Cat.No. Product Name Information/Activity
-
BCC6057
Teijin compound 1
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM.
-
BCC4447
Plerixafor 8HCl (AMD3100 8HCl)
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
-
BCC5182
AMD 3465 hexahydrobromide
AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses.
-
BCC6366
CTCE 9908
1030384-98-5
-
BCC7917
FC 131
606968-52-9
-
BCC6234
IT1t dihydrochloride
IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.
-
BCC8077
SB 225002
SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
-
BCC5936
SB 265610
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively.
-
BCC7910
TC 14012
368874-34-4
-
BCC4448
WZ811
WZ811 is an orally active, highly potent competitive antagonist of CXCR4. WZ811 efficiently inhibits CXCR4/SDF-1 (or CXCL12)-mediated modulation of cAMP levels (EC50=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC50=5.2 nM).


